Chronic Lower Back Pain Pipeline Offers Novel Treatment Options | 10+ Companies & 10+ Drugs

December 05 16:42 2022
Chronic Lower Back Pain Pipeline Offers Novel Treatment Options | 10+ Companies & 10+ Drugs

DelveInsight’s, “Chronic Lower Back Pain Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chronic Lower Back Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Chronic Lower Back Pain Pipeline Insight Report

  • DelveInsight’s Chronic Lower Back Pain pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Chronic Lower Back Pain treatment.
  • The leading Chronic Lower Back Pain Companies are working such as Mesoblast, Eli Lilly and Company, Persica Pharmaceuticals, CHABiotech, Allodynic Therapeutics, Stayble Therapeutics, Xgene Pharmaceutical, Imbrium Therapeutics, Camurus, and others.
  • Promising Chronic Lower Back Pain pipeline therapies such as buprenorphine, Duloxetine, EaseVRx headset with active intervention, AB001 patch, Flurbiprofen Tape (Arm 2), Bicifadine, and others.
  • The Chronic Lower Back Pain Companies and academics are working to assess challenges and seek opportunities that could influence Chronic Lower Back Pain R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Lower Back Pain.

 

Recent Developmental Activities in the Chronic Lower Back Pain Pipeline

  • MPC-06-ID is a tier 1 product candidate which consists of a unit dose of 6 million mesenchymal precursor cells (MPCs). It is injected by syringe directly into a targeted damaged disc in an outpatient procedure. MPC-06-ID is a Phase III product candidate for the treatment of chronic low back pain caused by disc degeneration (CLBP). It is being developed for patients who have exhausted conservative treatment options, may have failed epidural steroid injections and have no further treatment option other than invasive and costly surgical interventions.
  • PP353 is a unique combination of an antibiotic, a radio-opaque dye and a thermosensitive gel that provides a product for intradiscal injection. It is currently being studied in Phase I/II developmental studies for the treatment of patients with Chronic Low Back Pain associated with verterbral body endplate bone oedema.

 

Request a sample and discover the recent advances in Chronic Lower Back Pain treatment drugs @ Chronic Lower Back Pain Pipeline Outlook Report

 

Chronic Lower Back Pain Overview

Low back pain that has been present for longer than three months is considered as chronic, although there is still no consensus about the definition of Chronic Lower Back Pain (CLBP). 5-10% of all low back pain patients will develop CLBP. Chronic low back pain (CLBP) has been associated with neurochemical, structural, and functional cortical changes of several brain regions including the somatosensory cortex. Complex processes of peripheral and central sensitization may influence the evolution of acute to chronic pain. Most patients that suffer from CLBP experience pain in the lower area of the back (lumbar and sacroiliac regions) and mobility impairment. Diagnosis of low back pain is done on the basis of physical examination and patient history, sometimes followed by x-rays, CT scan, MRI, or other medical tests. Treatment for CLBP includes medications like acetaminophen (Tylenol), ibuprofen (Advil), and naproxen (Aleve). Physical therapy, occupational therapy, and lifestyle modification as well as other forms of exercise are also helpful.

 

Chronic Lower Back Pain Pipeline Insight Report

In the Chronic Lower Back Pain pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Lower Back Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Chronic Lower Back Pain Emerging Drugs Profile

  • MPC-06-ID: Mesoblast
  • PP353: Persica Pharmaceuticals

 

Chronic Lower Back Pain Pipeline Therapeutics Analysis

There are approx. 10+ key companies which are developing the therapies for Chronic Lower Back Pain. The companies which have their Chronic Lower Back Pain drug candidates in the most advanced stage, i.e. Phase III include, Mesoblast.

 

Find out more about Chronic Lower Back Pain drugs @ Chronic Lower Back Pain Treatment Landscape

 

Chronic Lower Back Pain Therapeutics Assessment

The Chronic Lower Back Pain pipeline report proffers an integral view of the Chronic Lower Back Pain emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

 

Scope of the Chronic Lower Back Pain Pipeline Report

  • Coverage- Global
  • Chronic Lower Back Pain Companies- Mesoblast, Eli Lilly and Company, Persica Pharmaceuticals, CHABiotech, Allodynic Therapeutics, Stayble Therapeutics, Xgene Pharmaceutical, Imbrium Therapeutics, Camurus, and others.
  • Chronic Lower Back Pain pipeline therapies- buprenorphine, Duloxetine, EaseVRx headset with active intervention, AB001 patch, Flurbiprofen Tape (Arm 2), Bicifadine, and others.
  • Chronic Lower Back Pain Unmet Needs, Market Drivers and Barriers

 

Dive deep into rich insights for drugs for Chronic Lower Back Pain Treatment, visit @ Chronic Lower Back Pain Clinical Trials Analysis

 

Table of Content

  1. Introduction
  2. Chronic Lower Back Pain Executive Summary
  3. Chronic Lower Back Pain: Overview
  4. Chronic Lower Back Pain Pipeline Therapeutics
  5. Chronic Lower Back Pain Therapeutic Assessment
  6. Chronic Lower Back Pain – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Chronic Lower Back Pain Collaboration Deals
  9. Late Stage Products (Phase III)
  10. MPC-06-ID: Mesoblast
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. LY3016859: Eli Lilly and Company
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I/II)
  16. PP353: Persica Pharmaceuticals
  17. Drug profiles in the detailed report…..
  18. Preclinical and Discovery Stage Products
  19. Drug name: Company name
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Chronic Lower Back Pain Key Companies
  23. Chronic Lower Back Pain Key Products
  24. Chronic Lower Back Pain- Unmet Needs
  25. Chronic Lower Back Pain- Market Drivers and Barriers
  26. Chronic Lower Back Pain- Future Perspectives and Conclusion
  27. Chronic Lower Back Pain Analyst Views
  28. Chronic Lower Back Pain Key Companies
  29. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Chronic Lower Back Pain drugs?
  • How many Chronic Lower Back Pain drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Lower Back Pain?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Lower Back Pain therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Chronic Lower Back Pain and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

For further information on the Chronic Lower Back Pain Pipeline therapeutics, reach out to Chronic Lower Back Pain Emerging Drugs

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

  Categories: